Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Original) A compound of formula (I):



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)- or -SO_2-;

R_1 and R_2 are each independently C_{1-8}-alkyl, CF_2H, CF_3, CH_2CHF_2, cycloalkyl, or (C_{1-8}-alkyl)cycloalkyl;

Z_1 is H, C_{1-6}-alkyl, NH_2, NR_3R_4 or OR_5;

Z_2 is H or C(O)R_5;

X_1, X_2, X_3 and X_4 are each independently H, halogen, NO_2, OR_3, CF_3, C_{1-6}-alkyl, (C_{0-4}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-4}-alkyl)-N-(R_8R_9), (C_{0-4}-alkyl)-NHC(O)-(R_8), (C_{0-4}-alkyl)-NHC(O)CH(R_8)(R_9), (C_{0-4}-alkyl)-NHC(O)N(R_8R_9), (C_{0-4}-alkyl)-NHC(O)O(R_8), (C_{0-4}-alkyl)-O-R_8, (C_{0-4}-alkyl)-imidazolyl, (C_{0-4}-alkyl)-pyrrolyl, (C_{0-4}-alkyl)-oxadiazolyl, (C_{0-4}-alkyl)-triazolyl or (C_{0-4}-alkyl)-heterocycle;

R_3, R_4, and R_5 are each independently H, C_{1-6}-alkyl, O-C_{1-6}-alkyl, phenyl, benzyl, or aryl;

R_6 and R_7 are independently H or C_{1-6}-alkyl;

R_8 and R_9 are each independently H, C_{1-9}-alkyl, C_{3-6}-cycloalkyl, (C_{1-6}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-6}-alkyl)-N(R_4R_5), (C_{1-6}-alkyl)-OR_5, phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrolidinyl, morpholino, or C_{3-7}-heterocycloalkyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) The compound of claim 1 wherein Y is -CH_2- or -C(O)-.

3. (Original) The compound of claim 1 wherein Z_1 is H.

4. (Original) The compound of claim 3 wherein R_6 is C_{1-6}-alkyl and R_7 is H.

5. (Original) The compound of claim 1 wherein Z_2 is H, $-C(O)CH_3$ or $-C(O)CH_2CH_3$.

6. (Original) The compound of claim 5 wherein X_4 is $NHC(O)R_8$.

7. (Original) The compound of claim 5 wherein R_1 is CH_3 or CF_2H and R_2 is C_{1-8}-alkyl.

8. (Original) The compound of claim 5 wherein Z_2 is H.

9. (Original) The compound of claim 1 wherein R_1 is CH_3 or CF_2H.

10. (Original) The compound of claim 1 wherein R_2 is CH_2CH_3, CH_3, CF_2H, CH_2-cyclopropyl, or cyclopentyl.

11. (Original) The compound of claim 1 wherein R_6 and R_7 are both H or one of R_6 and R_7 is H and the other is CH_3.

12. (Original) The compound of claim 1 wherein X_4 is $-NHC(O)R_8$ and X_1 is H or halogen.

13. (Original) The compound of claim 1 wherein one of X_1, X_2, X_3, and X_4 is $NHCOCH_2N(CH_3)_2$, $NHCON(CH_3)_2$, $NHCONH_2$, $NHCOCH_3$, $NHCOCH(R_8)N(R_7R_8)$ or OCH_3, and the rest of X_1, X_2, X_3, and X_4 are H.

14. (Original) The compound of claim 1, wherein the configuration of stereocenter **a** is (S).

15. (Original) The compound of claim 1, wherein the configuration of stereocenter **a** is (R).

16. (Original) The compound of claim 1, wherein R_6 and R_7 are not same, and the configuration of stereocenter **b** is (S).

17. (Original) The compound of claim 1, wherein R_6 and R_7 are not same, and the configuration of stereocenter **b** is (R).

18. (Original) A diastereomerically pure SS isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

19. (Original) A diastereomerically pure RS isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

20. (Original) A diastereomerically pure SR isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

21. (Original) A diastereomerically pure RR isomer of a compound of claim 1, substantially free of other diasteriomers, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

22. (Original) A compound, where the compound is:
(3R)-(tert-Butoxy)-N-{3-[7-(cyclopropylcarbonylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl}carbonylamino (tert-butoxy)formate;
N-[3-(7-Amino-1-oxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propyl](tert-butoxy)carbonylamino (tert-butoxy)formate;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide;
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;
(1R)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide;
(1R)-N-{2-[3-(N-Acetoxy-N-formyl-amino)-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;

(1R)-N-{2-[3-(N-Aminocarbonyl-N-hydroxy-amino)-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-isobutyramide;

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(N-formyl-N-hydroxy-amino)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(N-{3-[7-(Cyclopropylcarbonylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl}acetylamino) acetate; or

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-(formyl-hydroxy-amino)-butyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.

23. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula (I):



wherein:

Y is -C(O)-, $-CH_2-$, $-CH_2C(O)-$ or $-SO_2-$;

R_1 and R_2 are each independently C_{1-8}-alkyl, CF_2H, CF_3, CH_2CHF_2, cycloalkyl, or (C_{1-8}-alkyl)cycloalkyl;

Z_1 is H, C_{1-6}-alkyl, NH_2, NR_3R_4 or OR_5;

Z_2 is H or $C(O)R_5$;

X_1, X_2, X_3 and X_4 are each independently H, halogen, NO_2, OR_3, CF_3, C_{1-6}-alkyl, (C_{0-4}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-4}-alkyl)-N-(R_8R_9), (C_{0-4}-alkyl)-NHC(O)-(R_8), (C_{0-4}-alkyl)-NHC(O)CH(R_8)(R_9), (C_{0-4}-alkyl)-NHC(O)N(R_8R_9), (C_{0-4}-alkyl)-NHC(O)O(R_8), (C_{0-4}-alkyl)-O-R_8, (C_{0-4}-alkyl)-imidazolyl, (C_{0-4}-alkyl)-pyrrolyl, (C_{0-4}-alkyl)-oxadiazolyl, (C_{0-4}-alkyl)-triazolyl or (C_{0-4}-alkyl)-heterocycle;

R_3, R_4, and R_5 are each independently H, C_{1-6}-alkyl, O-C_{1-6}-alkyl, phenyl, benzyl, or aryl;

R_6 and R_7 are independently H or C_{1-6}-alkyl;

R_8 and R_9 are each independently H, C_{1-9}-alkyl, C_{3-6}-cycloalkyl, (C_{1-6}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-6}-alkyl)-N(R_4R_5), (C_{1-6}-alkyl)-OR_5, phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrolidinyl, morpholino, or C_{3-7}-heterocycloalkyl;

or a pharmaceutically acceptable salt or solvate thereof.

24. (Original) The pharmaceutical composition of claim 23 further comprising an additional therapeutic agent.

25. (Original) The pharmaceutical composition of claim 24 wherein the additional therapeutic agent is an anti-cancer agent or an anti-inflammatory agent.

26. (Original) The pharmaceutical composition of claim 25 wherein the anti-cancer agent is paclitaxel, cisplatin, tamoxifen, docetaxel, pirubicin, doxorubicin, irinotecan, leuprolide, bicalutamide, a goserlin implant, gemcitabine, sargramostim or a steroid.

Claims 27-57. Canceled without prejudice.